Assembly Biosciences, Inc. (ASMB) Stock Score, Valuation & Financial Research
Assembly Biosciences, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 33/100.
Quick answer for ASMB
Assembly Biosciences, Inc. currently has a Wall Street Score of 33/100. The stored market price is $29.8. Its financial score is 50/100. Its valuation score is 0/100. The latest WSS change is -0.1 points. These figures are a research snapshot, not a buy or sell recommendation.
What Assembly Biosciences, Inc. does
Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV. The company's development pipeline also features ABI-H3733, which has finished Phase 1a clinical studies, and ABI-4334, currently in pre-clinical assessment for HBV treatment. Assembly Biosciences has forged collaborative partnerships, including agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation, as well as with Antios Therapeutics, Inc., to explore a triple-combination treatment strategy for chronic hepatitis B virus. Additionally, it maintains strategic licensing arrangements with Indiana University Research and Technology Corporat
ASMB financial snapshot
- Wall Street Score:
- 33/100
- Current price:
- $29.8
- Market capitalization:
- $590.6M
- Revenue:
- $74.8M
- Net income:
- $-42K
- Free cash flow:
- $-41.2M
- Cash:
- $32.3M
- Total debt:
- $2.4M
- EPS:
- 0.55
- P/E ratio:
- 54.2x
- Financial score:
- 50/100
- Valuation score:
- 0/100
- Revenue score:
- 25/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $-41.2M, showing cash burn in the current stored period.
- The balance sheet shows $32.3M of cash versus $2.4M of total debt, leaving more cash than debt.
- The latest Wall Street Score change is -0.1 points: ASMB decreased 0.1 points because some fundamentals weakened.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 50/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-08.
How to research ASMB
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.